Literature DB >> 18089599

Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns.

Kurt Heim1, Gernot Hudelist, Andrea Geier, Hannes Szedenik, Neil D Christensen, Nicole Concin, Anton Bergant, Birgit Volgger, Klaus Czerwenka, Reinhard Höpfl.   

Abstract

Type-specific antibodies to human papillomaviruses (HPVs) can be detected in most infected adult patients, and they have virus-neutralizing properties. However, there is a dearth of information on the seroprevalence of maternal and neonatal antibodies to HPV capsid antigens. Sera from 104 mothers, their newborns, and 3 twin pregnancies were analyzed by an enzyme-linked immunosorbent assay (ELISA) for the presence of specific IgG, IgM, and IgA antibodies to virus-like particles of HPV-6, -11, -16, -18, and -31. Maternal IgG positivity rates to HPV types 6, 11, 16, 18, and 31 were 23.1%, 2.9%, 8.7%, 5.8%, and 9.6%, respectively. Neonatal rates did not differ significantly, and individual IgG ELISA values of mothers and their infants and all paired twins showed a very high correlation. In contrast, nearly all IgM and IgA individual values in newborns were designated negative, whereas mothers' positivity rates ranged as high as 19.2%. Infants showed no HPV-related lesions at birth or at 4-year follow-up. Seven of 8 tested children lost IgG HPV antibodies in a follow-up examination. Similar anti-HPV IgG seropositivity in mothers and newborns and a lack of neonatal IgA and IgM together with twin and follow-up results indicate that neonatal IgG is not a sign of intrauterine HPV infection but, rather, maternofetal antibody transmission.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089599     DOI: 10.1177/1933719107309546

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  6 in total

1.  Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine.

Authors:  Katie Matys; Sara Mallary; Oliver Bautista; Scott Vuocolo; Ricardo Manalastas; Punee Pitisuttithum; Alfred Saah
Journal:  Clin Vaccine Immunol       Date:  2012-04-18

Review 2.  Is administration of the HPV vaccine during pregnancy feasible in the future?

Authors:  Abbey B Berenson; Pooja R Patel; Alan D Barrett
Journal:  Expert Rev Vaccines       Date:  2013-11-28       Impact factor: 5.217

3.  Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

4.  Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age.

Authors:  Monica Zahreddine; Marie-Hélène Mayrand; Christian Therrien; Andrea Trevisan; Carole Dagenais; Patricia Monnier; Louise Laporte; Joseph Niyibizi; Catherine Deshaies; Ana Maria Carceller; William Fraser; Paul Brassard; Jacques Lacroix; Marie-Josée Bédard; Isabelle Girard; François Audibert; François Coutlée; Helen Trottier
Journal:  EClinicalMedicine       Date:  2020-04-07

5.  Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.

Authors:  Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

6.  Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life.

Authors:  Stina Syrjänen; Tim Waterboer; Marjut Rintala; Michael Pawlita; Kari Syrjänen; Karolina Louvanto; Seija Grenman
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.